

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	TTK protein kinase (TTK; MPS1)	<p><i>In vitro</i> and rat studies suggest a new class of MPS1 inhibitors could help treat cancer. <i>Ttk</i> knockdown has previously been shown to reduce survival and induce apoptosis in cancer cells. Chemical synthesis, SAR and <i>in vitro</i> testing identified several indazole analogs as selective, potent, nanomolar inhibitors of MPS1. Two lead compounds inhibited proliferation of a human lung cancer cell line at nanomolar IC₅₀ values and exhibited modest oral bioavailability in rats. Future studies could include improving the bioavailability of the lead compounds.</p> <p>SciBX 6(20); doi:10.1038/scibx.2013.490 Published online May 23, 2013</p>	Patent and licensing status unavailable	<p>Kusakabe, K.-i. <i>et al. J. Med. Chem.</i>; published online May 1, 2013; doi:10.1021/jm4000215</p> <p>Contact: Ken-ichi Kusakabe, Shionogi Pharmaceutical Research Center, Osaka, Japan e-mail: ken-ichi.kusakabe@shionogi.co.jp</p>